ARCHIVES

Comprehensive Centers Could Lose That Designation By Not Producing

This article is from The Cancer Letter archive.

Vol. 01 No. 22 | May 30, 1975

Download PDF Visit The Full Archive

Related Articles

In Brief NCI-FDA Relations Tops, DeVita Says; Upon Talks to Candidates For Prospective Division

November 24, 1978

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

November 2, 2007

DCBD Board Approves Recompetition Concepts, Including Cell Banks, Contrast Agents, Hepatoma Resources

November 14, 1980

Interferon Alpha-2B Effective For Malignant Melanoma

July 27, 2001

Phase II Study of Veliparib Improves PFS by 35 Percent

October 31, 2014

ASC Survey Leads to Strategic Plan Development, Office In Washington

June 9, 1989